AP-CAD Inc., Toronto, Ontario, Canada, M2N 3X2.
Advanced Pharmaceutics and Drug Delivery Laboratory, Leslie Dan Faculty of Pharmacy, University of Toronto, Ontario, Canada M5S 2S2.
J Control Release. 2016 Dec 10;243:11-20. doi: 10.1016/j.jconrel.2016.09.031. Epub 2016 Sep 29.
Nanoparticle formulations have found increasing applications in modern therapies. To achieve desired treatment efficacy and safety profiles, drug release kinetics of nanoparticles must be controlled tightly. However, actual drug release kinetics of nanoparticles cannot be readily measured due to technique difficulties, although various methods have been attempted. Among existing experimental approaches, dialysis method is the most widely applied one due to its simplicity and avoidance of separating released drug from the nanoparticles. Yet this method only measures the released drug in the medium outside a dialysis device (the receiver), instead of actual drug release from the nanoparticles inside the dialysis device (the donor). Thus we proposed a new method using numerical deconvolution to evaluate actual drug release kinetics of nanoparticles inside the donor based on experimental release profiles of nanoparticles and free drug solution in the receptor determined by existing dialysis tests. Two computer programs were developed based on two different numerical methods, namely least square criteria with prescribed Weibull function or orthogonal polynomials as input function. The former was used for all analyses in this work while the latter for verifying the reliability of the predictions. Experimental data of drug release from various nanoparticle formulations obtained from different dialysis settings and membrane pore sizes were used to substantiate this approach. The results demonstrated that this method is applicable to a broad range of nanoparticle and microparticle formulations requiring no additional experiments. It is independent of particle formulations, drug release mechanisms, and testing conditions. This new method may also be used, in combination with existing dialysis devices, to develop a standardized method for quality control, in vitro-in vivo correlation, and for development of nanoparticles and other types of dispersion formulations.
纳米颗粒制剂在现代治疗中得到了越来越多的应用。为了达到理想的治疗效果和安全性,必须严格控制纳米颗粒的药物释放动力学。然而,由于技术困难,实际上无法轻易测量纳米颗粒的实际药物释放动力学,尽管已经尝试了各种方法。在现有的实验方法中,由于其简单性和避免将释放的药物与纳米颗粒分离,透析法是应用最广泛的方法。然而,这种方法只能测量透析装置(受体)外部介质中释放的药物,而不能测量透析装置(供体)内纳米颗粒的实际药物释放。因此,我们提出了一种新的方法,使用数值反卷积法根据现有的透析试验确定的受体中纳米颗粒和游离药物溶液的实验释放曲线,评估供体中纳米颗粒的实际药物释放动力学。基于两种不同的数值方法,即规定威布尔函数或正交多项式作为输入函数的最小二乘准则,开发了两个计算机程序。前者用于本工作中的所有分析,后者用于验证预测的可靠性。使用来自不同透析设置和膜孔径的各种纳米颗粒制剂的药物释放实验数据来证实这种方法。结果表明,该方法适用于广泛的纳米颗粒和微颗粒制剂,无需额外的实验。它不依赖于颗粒制剂、药物释放机制和测试条件。这种新方法还可以与现有的透析装置结合使用,开发一种用于质量控制、体外-体内相关性以及纳米颗粒和其他类型分散制剂开发的标准化方法。